SlideShare a Scribd company logo
1 of 17
Download to read offline
Role of Human Kallikrein 7
Protease in Metastasis
Interns:
Shay Seguin
Sharmila Mitra
Nick Wong
Nick Higdon
Mentor: Jennifer Guerrero
Advisor: Professor Patrick Daugherty
SIMS, University of California, Santa Barbara
90% of Cancer Deaths Are Associated With
the Spreading of a Tumor
Tumor
Blood Vessel
Secondary
Tumor
http://www.wpclipart.com/
Role of Protease in Biological Functions
Cell Adhesion
Proteins
Dead Skin Cell
Healthy Skin Cell
hK7 Protease
hK7
Role of Protease in the Spreading of Cancer
Cancer Cells
Healthy Cells
Cell Adhesion
Substrates
Protease
Courtesy of Jennifer Guerrero
Which Substrates Break Down the Fastest
hK7 Protein
Substrate
Substrates
• Fibronectin
• Desmocollin-1
• Desmoglein-1
• Desmoglein-2
• E-cadherin
Binding
Cleavage
Determine if an Inhibitor Can Effectively Block hK7
hK7
Protein
Substrate
Inhibitor
No Binding
No Cleavage
Using FRET Protein to Test Protease Activity
Yellow: no cleavage
Cyan: cleavage
Substrate
FRET: Förster Resonance Energy Transfer
Courtesy of Jennifer Guerrero
hK7
Preparing the Bacteria for Protein Production
Plasmid DNA
Gene Coding
FRET Substrate
Arabinose Promoter
Courtesy of Jennifer Guerrero openwetware.org
E. coli
Target Protein
0.00
0.10
0.20
0.30
0.40
0.50
0 30 60 90 125
Time (minutes)
Add Arabinose
“On Switch”
Culturing E. coli for Substrate Production
Cell Density
(1x10^9 cell/mL)
Add BPER II Detergent
Spin Down in Centrifuge
Purifying FRET Proteins in E. coli
Target Protein
Excess Protein
Dead E. coli
Live E. coli
Target Protein
Excess Protein
Nickel Beads
Mesh Filter
Purifying FRET Proteins in E. coli
250 mM Imidazole Wash
Measuring Substrate Cleavage With
Fluorimeter
hK7 FRET
Substrate
Substrates
• Fibronectin
• Desmocollin-1
• Desmoglein-1
• Desmoglein-2
• E-cadherin
+
0%
20%
40%
60%
80%
100%
0 40 80 120 160 200 240
PercentageofSubstrateCleaved
Time (Minutes)
Ratio of Substrate to Substrate Cleavage
Percentage of Substrate Cleaved in 1 Hour
10%
77%
81%
92%
95%
Desmoglein-2
Fibronectin
E-cadherin
Desmocollin-1
Desmoglein-1
Demonstrating the Effect of an Inhibitor
on hK7 Activity
3%
95%
With Inhibitor
Without Inhibitor
Percentage of Substrate Cleaved in 1 Hour
Desmoglein-1
Cancer Cells
Healthy Cells
Cell Adhesion
Substrates
Protease With Inhibitor
Protease Inhibitors as Cancer Therapeutics
Acknowledgements
Special thanks to:
Mentor: Jennifer Guerrero
Advisor: Professor Patrick Daugherty
SIMS Staff:
Ofelia Aguirre
Jonathan Cook
Stephanie Mendes
Dean Morales
Andrew Dawson
Kori Lay
Kuang Wei
Mary Lou Bailey

More Related Content

What's hot

Dougherty Reeves Lucas Gamble Lesort Cowell 2012
Dougherty Reeves Lucas Gamble Lesort Cowell 2012Dougherty Reeves Lucas Gamble Lesort Cowell 2012
Dougherty Reeves Lucas Gamble Lesort Cowell 2012
Elizabeth Lucas
 
Poster_NHGRI_DahliaShvets.ver2
Poster_NHGRI_DahliaShvets.ver2Poster_NHGRI_DahliaShvets.ver2
Poster_NHGRI_DahliaShvets.ver2
Dahlia Shvets
 
Lack of association between CD45 C77G polymorphism and multiple sclerosis in ...
Lack of association between CD45 C77G polymorphism and multiple sclerosis in ...Lack of association between CD45 C77G polymorphism and multiple sclerosis in ...
Lack of association between CD45 C77G polymorphism and multiple sclerosis in ...
ijtsrd
 
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell TransplantationCellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
spa718
 
MOLECULAR BIOLOGY FOLDING
MOLECULAR BIOLOGY FOLDINGMOLECULAR BIOLOGY FOLDING
MOLECULAR BIOLOGY FOLDING
AndreaFacioG
 

What's hot (20)

Dougherty Reeves Lucas Gamble Lesort Cowell 2012
Dougherty Reeves Lucas Gamble Lesort Cowell 2012Dougherty Reeves Lucas Gamble Lesort Cowell 2012
Dougherty Reeves Lucas Gamble Lesort Cowell 2012
 
Poster_NHGRI_DahliaShvets.ver2
Poster_NHGRI_DahliaShvets.ver2Poster_NHGRI_DahliaShvets.ver2
Poster_NHGRI_DahliaShvets.ver2
 
P53 poster
P53 posterP53 poster
P53 poster
 
Lack of association between CD45 C77G polymorphism and multiple sclerosis in ...
Lack of association between CD45 C77G polymorphism and multiple sclerosis in ...Lack of association between CD45 C77G polymorphism and multiple sclerosis in ...
Lack of association between CD45 C77G polymorphism and multiple sclerosis in ...
 
Cell cycle
Cell cycleCell cycle
Cell cycle
 
KFU Invited seminar
KFU Invited seminarKFU Invited seminar
KFU Invited seminar
 
Targeting p53 for novel anticancer therapy
Targeting p53 for novel anticancer therapyTargeting p53 for novel anticancer therapy
Targeting p53 for novel anticancer therapy
 
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell TransplantationCellular Immune Therapy with Allogeneic Stem Cell Transplantation
Cellular Immune Therapy with Allogeneic Stem Cell Transplantation
 
p53 and cancer
 p53 and cancer p53 and cancer
p53 and cancer
 
p53
p53p53
p53
 
NetBioSIG2014-Talk by Salvatore Loguercio
NetBioSIG2014-Talk by Salvatore LoguercioNetBioSIG2014-Talk by Salvatore Loguercio
NetBioSIG2014-Talk by Salvatore Loguercio
 
Role of p53 gene
Role of p53 gene Role of p53 gene
Role of p53 gene
 
Exploring the role of Epigenetic regulation in plant disease management
Exploring the role of Epigenetic regulation in plant disease managementExploring the role of Epigenetic regulation in plant disease management
Exploring the role of Epigenetic regulation in plant disease management
 
CGI.Paper
CGI.PaperCGI.Paper
CGI.Paper
 
Structure of p53 protein
Structure of p53 proteinStructure of p53 protein
Structure of p53 protein
 
MOLECULAR BIOLOGY FOLDING
MOLECULAR BIOLOGY FOLDINGMOLECULAR BIOLOGY FOLDING
MOLECULAR BIOLOGY FOLDING
 
Precision Breeding in Plants
Precision Breeding in PlantsPrecision Breeding in Plants
Precision Breeding in Plants
 
P53
P53P53
P53
 
Presentation
PresentationPresentation
Presentation
 
THE GUARDIAN ANGEL OF GENOME P53 IN CANCER TREATMENT
THE GUARDIAN ANGEL OF GENOME P53 IN CANCER TREATMENTTHE GUARDIAN ANGEL OF GENOME P53 IN CANCER TREATMENT
THE GUARDIAN ANGEL OF GENOME P53 IN CANCER TREATMENT
 

Similar to project_1_sims

Hao Liu Resume 2017-02
Hao Liu Resume 2017-02Hao Liu Resume 2017-02
Hao Liu Resume 2017-02
Hao Liu
 
Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...
Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...
Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...
Angela Farngren
 
seminar on prostate cancer and awareness.ppt
seminar on prostate cancer and awareness.pptseminar on prostate cancer and awareness.ppt
seminar on prostate cancer and awareness.ppt
Ogunsina1
 
PhD Poster - UKEMS Conference 2008
PhD Poster - UKEMS Conference 2008PhD Poster - UKEMS Conference 2008
PhD Poster - UKEMS Conference 2008
Donna Johnson
 

Similar to project_1_sims (20)

Cupid Peptides presentation wjr
Cupid Peptides presentation wjrCupid Peptides presentation wjr
Cupid Peptides presentation wjr
 
Prostate BPH- pathophysiology
Prostate  BPH- pathophysiologyProstate  BPH- pathophysiology
Prostate BPH- pathophysiology
 
Radiation protection,protease inhibition.
Radiation protection,protease inhibition.Radiation protection,protease inhibition.
Radiation protection,protease inhibition.
 
Hao Liu Resume 2017-02
Hao Liu Resume 2017-02Hao Liu Resume 2017-02
Hao Liu Resume 2017-02
 
Targeting p53 for Novel Anticancer Therapy
Targeting p53 for Novel Anticancer TherapyTargeting p53 for Novel Anticancer Therapy
Targeting p53 for Novel Anticancer Therapy
 
inducing Apoptosis in cancer cell by natural compounds and screening methods
inducing Apoptosis in cancer cell by natural compounds and screening methodsinducing Apoptosis in cancer cell by natural compounds and screening methods
inducing Apoptosis in cancer cell by natural compounds and screening methods
 
Epigenetics & Gene Control
Epigenetics & Gene ControlEpigenetics & Gene Control
Epigenetics & Gene Control
 
article
articlearticle
article
 
oncogenes and tumour supressor genes
oncogenes and tumour supressor genesoncogenes and tumour supressor genes
oncogenes and tumour supressor genes
 
Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...
Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...
Evaluation of the changes in the gene CYP3A4 expression in HepG2 cells under ...
 
Python Meetup2014 (Ying Liu)
Python Meetup2014 (Ying Liu)Python Meetup2014 (Ying Liu)
Python Meetup2014 (Ying Liu)
 
seminar on prostate cancer and awareness.ppt
seminar on prostate cancer and awareness.pptseminar on prostate cancer and awareness.ppt
seminar on prostate cancer and awareness.ppt
 
Guillian-Barre.Therapy.Experimental.
Guillian-Barre.Therapy.Experimental.Guillian-Barre.Therapy.Experimental.
Guillian-Barre.Therapy.Experimental.
 
Non alcoholic steatohepatitis METABOLIC APPROACH.pptx
Non alcoholic steatohepatitis METABOLIC APPROACH.pptxNon alcoholic steatohepatitis METABOLIC APPROACH.pptx
Non alcoholic steatohepatitis METABOLIC APPROACH.pptx
 
Identifying novel and druggable targets in a triple negative breast cancer ce...
Identifying novel and druggable targets in a triple negative breast cancer ce...Identifying novel and druggable targets in a triple negative breast cancer ce...
Identifying novel and druggable targets in a triple negative breast cancer ce...
 
Protein folding and proteostasis
Protein folding and proteostasisProtein folding and proteostasis
Protein folding and proteostasis
 
P53.pptx
P53.pptxP53.pptx
P53.pptx
 
PhD Poster - UKEMS Conference 2008
PhD Poster - UKEMS Conference 2008PhD Poster - UKEMS Conference 2008
PhD Poster - UKEMS Conference 2008
 
ASH2213Msc105M-oncology-p53-based Cancer Therapy.pptx
ASH2213Msc105M-oncology-p53-based Cancer Therapy.pptxASH2213Msc105M-oncology-p53-based Cancer Therapy.pptx
ASH2213Msc105M-oncology-p53-based Cancer Therapy.pptx
 
Ngs update
Ngs updateNgs update
Ngs update
 

project_1_sims

  • 1. Role of Human Kallikrein 7 Protease in Metastasis Interns: Shay Seguin Sharmila Mitra Nick Wong Nick Higdon Mentor: Jennifer Guerrero Advisor: Professor Patrick Daugherty SIMS, University of California, Santa Barbara
  • 2. 90% of Cancer Deaths Are Associated With the Spreading of a Tumor Tumor Blood Vessel Secondary Tumor http://www.wpclipart.com/
  • 3. Role of Protease in Biological Functions Cell Adhesion Proteins Dead Skin Cell Healthy Skin Cell hK7 Protease hK7
  • 4. Role of Protease in the Spreading of Cancer Cancer Cells Healthy Cells Cell Adhesion Substrates Protease Courtesy of Jennifer Guerrero
  • 5. Which Substrates Break Down the Fastest hK7 Protein Substrate Substrates • Fibronectin • Desmocollin-1 • Desmoglein-1 • Desmoglein-2 • E-cadherin Binding Cleavage
  • 6. Determine if an Inhibitor Can Effectively Block hK7 hK7 Protein Substrate Inhibitor No Binding No Cleavage
  • 7. Using FRET Protein to Test Protease Activity Yellow: no cleavage Cyan: cleavage Substrate FRET: Förster Resonance Energy Transfer Courtesy of Jennifer Guerrero hK7
  • 8. Preparing the Bacteria for Protein Production Plasmid DNA Gene Coding FRET Substrate Arabinose Promoter Courtesy of Jennifer Guerrero openwetware.org E. coli Target Protein
  • 9. 0.00 0.10 0.20 0.30 0.40 0.50 0 30 60 90 125 Time (minutes) Add Arabinose “On Switch” Culturing E. coli for Substrate Production Cell Density (1x10^9 cell/mL)
  • 10. Add BPER II Detergent Spin Down in Centrifuge Purifying FRET Proteins in E. coli Target Protein Excess Protein Dead E. coli Live E. coli
  • 11. Target Protein Excess Protein Nickel Beads Mesh Filter Purifying FRET Proteins in E. coli 250 mM Imidazole Wash
  • 12. Measuring Substrate Cleavage With Fluorimeter hK7 FRET Substrate Substrates • Fibronectin • Desmocollin-1 • Desmoglein-1 • Desmoglein-2 • E-cadherin +
  • 13. 0% 20% 40% 60% 80% 100% 0 40 80 120 160 200 240 PercentageofSubstrateCleaved Time (Minutes) Ratio of Substrate to Substrate Cleavage
  • 14. Percentage of Substrate Cleaved in 1 Hour 10% 77% 81% 92% 95% Desmoglein-2 Fibronectin E-cadherin Desmocollin-1 Desmoglein-1
  • 15. Demonstrating the Effect of an Inhibitor on hK7 Activity 3% 95% With Inhibitor Without Inhibitor Percentage of Substrate Cleaved in 1 Hour Desmoglein-1
  • 16. Cancer Cells Healthy Cells Cell Adhesion Substrates Protease With Inhibitor Protease Inhibitors as Cancer Therapeutics
  • 17. Acknowledgements Special thanks to: Mentor: Jennifer Guerrero Advisor: Professor Patrick Daugherty SIMS Staff: Ofelia Aguirre Jonathan Cook Stephanie Mendes Dean Morales Andrew Dawson Kori Lay Kuang Wei Mary Lou Bailey